| Subject: | FDA Approves Resumed Marketing of Tysabri Under a Special Distribution Program |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Wed, 7 Jun 2006 - 10:00 am |
| Audience: Neurological and other healthcare professionals, patients
The FDA has approved resumed marketing of Tysabri (natalizumab) subject to a special restricted distribution program. Tysabri is a monoclonal antibody used to treat patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of exacerbations/ flare-ups. Tysabri is indicated for use as a monotherapy, and is for patients who have not responded adequately to, or cannot tolerate, other treatments for... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
REFERENCE:
External Links:
|
|
StayAlert! provides immediate online healthcare compliance validation to our healthcare users. When faced with dramatic reductions in healthcare dollars, StayAlert! focuses on those processes that can save the most time and money. By automating labor-intensive activities, StayAlert! almost instantly produces a positive impact on the healthcare user's bottom line. The policies alone included with the StayAlert! notices can save you $65,000 or more in labor costs each year. Organizations will realize dramatic cost savings through elimination of labor intensity, increased productivity with the benefit of ensuring regulatory compliance. StayAlert! is the service-oriented supplier of health care's compliance needs. The StayAlert! system was designed by healthcare professionals actively working in the healthcare environment, who were faced with attempting to competently provide quality care and services while "doing more with less". StayAlert! provides the answer to efficiently performing a variety of required job components from one centralized virtual location. StayAlert! improves data sharing and communications, thus reducing cost, broadening access and providing a system of documentation and follow-up. |
|